Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Item

http://www.wikidata.org/entity/Q37234829

Q37234829

about

Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/- mice Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer?Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Advances in chemical pharmacotherapy to manage advanced breast cancer.New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527 Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.Tumor vasculogenic mimicry formation as an unfavorable prognostic indicator in patients with breast cancer.Emerging data on improving response to hormone therapy: the role of novel targeted agents.Update Breast Cancer 2017 - Implementation of Novel Therapies.Antiangiogenic therapy in breast cancer.Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway.Progress in targeted therapy for breast cancer

P2860

Q31157714-D98D5CB3-D10F-48F5-BE58-CF46AF8A5330 Q33656801-CE94AF36-9E4B-4423-B5E8-F7BCB5E5414B Q33799297-0E877CC3-E122-44A0-8ED4-8B1F75EC3268 Q38661501-4475BF31-E557-4E3B-8B8C-DD7F1A0F8A76 Q38662999-89B068E0-4491-40BB-A9CD-C73CEFAC00E2 Q38683638-D580FD3D-1A47-42CF-AE46-BE4B00D0AA4A Q38786066-3A35A98F-37B0-4191-9F75-A3DBBCF61B67 Q38809459-F31F277F-B65D-481C-8511-457D79683133 Q38870640-B4E809E7-F2C7-4482-A9C9-969AD434DAC8 Q39089103-1CD324DE-5BA3-4F42-BC54-5249D0F84679 Q39172983-49F6C5C9-B454-4480-BEBD-475CDDE6FDF7 Q39402106-7509B0A9-40D1-4D71-BABF-3EC39A85E112 Q41346466-6E9FEA3C-ADF1-43E9-9D2A-64B72150E089 Q46537162-8ADB1E5E-80C4-44D9-8262-5B4CE4617B74 Q47110841-664B52F0-74E0-41AF-8AF3-F3AD08D10B8A Q47111400-8D326905-0AE0-4850-8F05-37BDD15E5B39 Q47561979-5E542A5A-C847-4A38-9513-E74F22F12E03 Q50114923-6427EC17-A9C1-40DF-81F8-0254E0E771D1 Q50419857-D6C7D0D1-363C-4352-9E4E-BEF487F0B26F Q54957190-72CE4EA5-C220-41EE-8DD5-E886D571C45A Q54978022-FAD1C3C5-23E0-40A2-8457-F473A8FE09FF Q57109788-4BD41DAB-556C-4648-9AF2-126CC355DD96

P2860

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Item

http://www.wikidata.org/entity/Q37234829

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase III Trial Evaluating Let ...... Cancer: CALGB 40503 (Alliance)

@en

Phase III Trial Evaluating Let ...... age Breast Cancer: CALGB 40503

@nl

type

Item

label

Phase III Trial Evaluating Let ...... Cancer: CALGB 40503 (Alliance)

@en

Phase III Trial Evaluating Let ...... age Breast Cancer: CALGB 40503

@nl

prefLabel

Phase III Trial Evaluating Let ...... Cancer: CALGB 40503 (Alliance)

@en

Phase III Trial Evaluating Let ...... age Breast Cancer: CALGB 40503

@nl

P1476

Phase III Trial Evaluating Let ...... Cancer: CALGB 40503 (Alliance)

@en

P2093

Arti Hurria

http://www.w3.org/2001/XMLSchema#string

Bryan P Schneider

http://www.w3.org/2001/XMLSchema#string

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Constance T Cirrincione

http://www.w3.org/2001/XMLSchema#string

Debasish Tripathy

http://www.w3.org/2001/XMLSchema#string

Diana E Lake

http://www.w3.org/2001/XMLSchema#string

Eric P Winer

http://www.w3.org/2001/XMLSchema#string

Federico Innocenti

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

Lisa A Carey

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Combination anastrozole and fulvestrant in metastatic breast cancer

Comprehensive molecular portraits of human breast tumours

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Molecular portraits of human breast tumours

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Tumor angiogenesis

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

P304

2602-2609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.66.1595

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27138575

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

phase III clinical trial

P932

5012690

http://www.w3.org/2001/XMLSchema#string

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

about

P2860

P2860

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932